The decision supports Moderna’s use of SM-102 in its Spikevax COVID-19 vaccine. 3 Summer "Power Patterns" Are About to Trigger (One With 90% Win ... case centered on whether Alnylam’s patents ...

At the center of the case was whether Alnylam’s patents, U.S. Patent Nos. 11,246,933 and 11,382,979, were infringed by Moderna’s use of SM-102-a cationic lipid used in Moderna’s COVID-19 ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

Moderna’s Covid shot had previously been approved for people 12 years of age and older regardless of their underlying health.

Moderna's COVID shot had previously been approved for people 12 years of age and older regardless of their underlying health. Vaccine makers have been on high alert to challenges under Kennedy ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

Moderna (NASDAQ:MRNA) announced on Saturday that the U.S. Food and Drug Administration (FDA) approved its next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283), making it the Cambridge, Massachusetts ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved next-gen COVID-19 vaccine. Read more here.